Fortress and private equity firm Centerbridge Partners, which had agreed in June to buy Penn for $67 a share will now instead invest in the casino operator and pay a termination fee. Penn stock had declined 44% since last June. Fortress was trading down about 1% to $11.39; Penn was up 3% to $29.45.
Wachovia (WB - Get Report) dropped 3.1% to $14.90. The bank announced that it appointed Kevin O'Connor as its chief investment officer to Wachovia Global Securities Lending, a division of the bank that handles third-party lending.
Chindex International (CHDX) said Wednesday post close that it received approval from health regulators in the People's Republic of China to introduce new products, including Intuitive Surgical's (ISRG - Get Report) daVinci S. Surgical System. Chindex shares rose 15% to $16.13 Thursday, and Intuitive Surgical's shares edged down 0.2% to $250.57.Abbott Laboratories (ABT - Get Report) shares climbed on the Food and Drug Administration approval of its Xience V, a drug-eluting stent for patients with coronary artery disease. The antibiotic-coated mesh tube will compete with products by Boston Scientific (BSX - Get Report), Medtronic (MDT) and Johnson & Johnson (JNJ). Abbott, which said it will launch the stent in the U.S. immediately, saw shares rise 1% to $54.80. Shares of competitor Boston Scientific, which makes the Taxus stent, edged down 4 cents to $12.37.